Inozyme Pharma Inc (INZY)

Currency in USD
4.000
+0.010(+0.25%)
Closed·
Showing Inozyme historical data. For real-time data please try another search
Fair Value
Day's Range
3.9904.000
52 wk Range
0.7216.240
Key Statistics
Prev. Close
4
Open
4
Day's Range
3.99-4
52 wk Range
0.721-6.24
Volume
1.46M
Average Volume (3m)
2.26M
1-Year Change
-7.62%
Book Value / Share
0.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INZY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Inozyme Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Inozyme Pharma Inc Company Profile

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. As of July 1, 2025, Inozyme Pharma, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc..

Compare INZY to Peers and Sector

Metrics to compare
INZY
Peers
Sector
Relationship
P/E Ratio
−2.4x0.0x−0.5x
PEG Ratio
0.110.000.00
Price/Book
8.2x0.0x2.6x
Price / LTM Sales
-0.0x3.3x
Upside (Analyst Target)
0.0%0.0%43.4%
Fair Value Upside
Unlock0.0%7.1%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.44 / -0.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

INZY Income Statement

People Also Watch

20.15
TSSI
-8.86%
247.45
AVAV
-4.68%
120.41
CRDO
+0.53%
2.070
VOR
0.00%
16.900
QBTS
-1.57%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.